Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKLI NASDAQ:GUTS NASDAQ:MBOT NASDAQ:RCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKLIAkili$0.43$0.43$0.19▼$1.25$34.01M1.722.20 million shsN/AGUTSFractyl Health$0.78+2.4%$0.78$0.38▼$2.45$123.75M2.293.69 million shs57,613 shsMBOTMicrobot Medical$1.94+1.3%$1.92$1.60▼$4.67$129.30M1.041.73 million shs70,903 shsRCELAvita Medical$5.04-0.3%$4.26$3.22▼$7.12$155.19M1.86254,898 shs39,506 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKLIAkili0.00%0.00%0.00%0.00%0.00%GUTSFractyl Health0.00%+2.56%+12.29%+66.74%-53.39%MBOTMicrobot Medical0.00%+7.61%+3.80%-19.07%-26.54%RCELAvita Medical0.00%+27.46%+21.05%+29.74%-8.25%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKLIAkili$0.43$0.43$0.19▼$1.25$34.01M1.722.20 million shsN/AGUTSFractyl Health$0.78+2.4%$0.78$0.38▼$2.45$123.75M2.293.69 million shs57,613 shsMBOTMicrobot Medical$1.94+1.3%$1.92$1.60▼$4.67$129.30M1.041.73 million shs70,903 shsRCELAvita Medical$5.04-0.3%$4.26$3.22▼$7.12$155.19M1.86254,898 shs39,506 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKLIAkili0.00%0.00%0.00%0.00%0.00%GUTSFractyl Health0.00%+2.56%+12.29%+66.74%-53.39%MBOTMicrobot Medical0.00%+7.61%+3.80%-19.07%-26.54%RCELAvita Medical0.00%+27.46%+21.05%+29.74%-8.25%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKLIAkili 0.00N/AN/AN/AGUTSFractyl Health 2.50Moderate Buy$5.12556.41% UpsideMBOTMicrobot Medical 2.60Moderate Buy$6.63242.38% UpsideRCELAvita Medical 2.43Hold$7.2543.76% UpsideCurrent Analyst Ratings BreakdownLatest AKLI, RCEL, GUTS, and MBOT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2026GUTSFractyl Health Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$4.007/1/2026GUTSFractyl Health Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$4.006/30/2026RCELAvita Medical TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/24/2026RCELAvita Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/4/2026GUTSFractyl Health HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.006/3/2026MBOTMicrobot Medical Loop CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$4.005/15/2026RCELAvita Medical Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$3.50 ➝ $6.005/12/2026GUTSFractyl Health Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/24/2026GUTSFractyl Health HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.004/14/2026MBOTMicrobot Medical HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.004/10/2026MBOTMicrobot Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKLIAkili$1.95M17.46N/AN/A$0.75 per share0.58GUTSFractyl Health$90K1,374.97N/AN/A$0.07 per share11.14MBOTMicrobot MedicalN/AN/AN/AN/A$1.15 per shareN/ARCELAvita Medical$71.61M2.17N/AN/A($0.55) per share-9.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKLIAkili-$59.49M-$0.61N/AN/AN/A-2,492.04%-79.93%-59.16%N/AGUTSFractyl Health-$140.95M-$1.29N/AN/AN/AN/A-4,053.15%-96.41%8/11/2026 (Estimated)MBOTMicrobot Medical-$13.14M-$0.26N/AN/AN/AN/A-21.84%-20.71%8/11/2026 (Estimated)RCELAvita Medical-$48.59M-$1.57N/AN/AN/A-62.67%N/A-78.92%8/6/2026 (Estimated)Latest AKLI, RCEL, GUTS, and MBOT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026RCELAvita Medical-$0.35-$0.35N/A-$7.00$18.30 million$19.25 million5/13/2026Q1 2026MBOTMicrobot Medical-$0.08-$0.05+$0.03-$0.05$0.30 million$0.11 million5/12/2026Q1 2026GUTSFractyl Health-$0.17$0.06+$0.23$0.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAKLIAkiliN/AN/AN/AN/AN/AGUTSFractyl HealthN/AN/AN/AN/AN/AMBOTMicrobot MedicalN/AN/AN/AN/AN/ARCELAvita MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKLIAkili0.085.805.80GUTSFractyl Health1.414.284.28MBOTMicrobot Medical0.0122.5921.93RCELAvita MedicalN/A0.470.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKLIAkili53.12%GUTSFractyl HealthN/AMBOTMicrobot Medical16.30%RCELAvita Medical27.66%Insider OwnershipCompanyInsider OwnershipAKLIAkili10.10%GUTSFractyl Health8.52%MBOTMicrobot Medical4.74%RCELAvita Medical2.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKLIAkili13078.73 million70.78 millionNo DataGUTSFractyl Health102158.65 million145.13 millionN/AMBOTMicrobot Medical2067.17 million63.98 millionOptionableRCELAvita Medical13030.78 million29.92 millionOptionableAKLI, RCEL, GUTS, and MBOT HeadlinesRecent News About These CompaniesAvita Medical (NASDAQ:RCEL) Rating Increased to Hold at Wall Street ZenJuly 4 at 1:36 AM | americanbankingnews.comAvita Medical (RCEL) Upgraded to Buy: Here's WhyJuly 3 at 1:00 PM | zacks.comAvita Medical Inc. (NASDAQ:RCEL) Given Consensus Recommendation of "Hold" by AnalystsJune 30, 2026 | americanbankingnews.comAVITA Medical Highlights First U.K. Clinical Experience with RECELL GO at British Burn Association Annual MeetingJune 18, 2026 | markets.businessinsider.comAvita Medical (NASDAQ:RCEL) Director Purchases $20,800.00 in StockJune 11, 2026 | insidertrades.comAvita Medical (NASDAQ:RCEL) Director Purchases $41,900.00 in StockJune 10, 2026 | insidertrades.comAvita Medical (NASDAQ:RCEL) Director Purchases $40,900.00 in StockJune 6, 2026 | insidertrades.comAvita Medical (NASDAQ:RCEL) Director Buys $43,000.00 in StockJune 4, 2026 | insidertrades.comAVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Prepared Remarks TranscriptJune 3, 2026 | seekingalpha.comAVITA Medical, Inc. (RCEL) Discusses Business Progress, Operational Changes and Sequential Revenue Growth TranscriptMay 22, 2026 | seekingalpha.comAVITA Medical to Host Investor Webinar BriefingMay 17, 2026 | globenewswire.comBTIG Reaffirms Their Hold Rating on Avita Medical (RCEL)May 17, 2026 | theglobeandmail.comLake Street upgrades AVITA Medical (RCEL)May 16, 2026 | msn.comAvita (RCEL) Q1 2026 Earnings Call TranscriptMay 15, 2026 | theglobeandmail.comAVITA Medical, Inc. (RCEL) Q1 2026 Earnings Call TranscriptMay 14, 2026 | seekingalpha.comAVITA Medical Reports First Quarter 2026 Financial ResultsMay 14, 2026 | globenewswire.comAVITA Medical Names Cary Vance as Chief Executive OfficerApril 30, 2026 | globenewswire.comAVITA Medical Announces TGA Certification in Australia and Medsafe WAND Listing in New Zealand for RECELL GOApril 29, 2026 | globenewswire.comAVITA Medical to Announce First Quarter 2026 Financial ResultsApril 23, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical Inc. - RCELApril 21, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 2026These 5 Companies Just Made a Massive Bet on ThemselvesBy Thomas Hughes | June 15, 20263 European Stocks to Carry Investors Through the Back Half of 2026By Chris Markoch | July 1, 2026AKLI, RCEL, GUTS, and MBOT Company DescriptionsAkili NASDAQ:AKLIAkili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts.Fractyl Health NASDAQ:GUTS$0.78 +0.02 (+2.36%) As of 10:10 AM Eastern This is a fair market value price provided by Massive. Learn more.Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.Microbot Medical NASDAQ:MBOT$1.94 +0.03 (+1.31%) As of 10:10 AM Eastern This is a fair market value price provided by Massive. Learn more.Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.Avita Medical NASDAQ:RCEL$5.04 -0.02 (-0.34%) As of 10:10 AM Eastern This is a fair market value price provided by Massive. Learn more.AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Analysts Just Raised Price Targets On These 3 Semiconductor Equipment Stocks Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst This Under-the-Radar Industrial Is Quietly Powering AI SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
